We chose to isolate and analyze olaparib-resistant clones from both HRR-deficient and -proficient cell lines because of recent studies showing that patients with each molecular subtype of ovarian cancer can benefit from PARP inhibitor therapy [17,18,19]. This evidence concerns the gene PARP1 and ovarian carcinoma.